US4409239A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Propylene glycol diester solutions of PGE-type compounds
Assignee: Syntex USA LLC
•
Filing: 1982-01-21
•
Granted: 1983-10-11
•
Expires: 2002-01-21
Abstract
Abstract Stable compositions of PGE and PGE-type compounds are achieved by dissolving these compounds in propylene glycol diesters of short chain fatty acids.
Inventors
- 👤 Cheng-Der Yu
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 07:07
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/557; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K9/00; A61K9/48; A61K9/4841; A61K9/4858
Claims Analysis
Total Claims: 36
Claim 1
Independent Claim
30 words
A stable pharmaceutical composition of a PGE or PGE-type compound comprising a solution of said compound in a solvent comprising at least propylene glycol diester of short chain fatty acid.
Claim 2
Dependent Claim
30 words
A stable pharmaceutical composition of a PGE or PGE-type compound comprising a solution of said compound in a solvent comprising at least propylene glycol diester of short chain fatty acid.
Claim 3
Dependent Claim
22 words
A composition according to claim 1 wherein said compound is present in an amount between 0.001 mg to 100 mg/ml of solvent.
Claim 4
Dependent Claim
20 words
A composition according to claim 2 wherein said solvent comprises a propylene glycol dicaprylate or dicaprate or a mixture thereof.
Claim 5
Dependent Claim
20 words
A composition according to claim 2 wherein said solution is contained in a capsule of a pharmaceutically acceptable water-dispersible material.
Claim 6
Dependent Claim
12 words
A composition according to claim 4 wherein said water-dispersible material is gelatin.
Claim 7
Dependent Claim
22 words
A composition according to claim 2 wherein said compound is present in an amount between 0.01 mg to 20 mg/ml of solvent.
Claim 8
Dependent Claim
17 words
A composition according to claim 6 wherein said solution is contained in a pharmaceutically acceptable water-dispersible material.
Claim 9
Dependent Claim
19 words
A composition according to claim 7 wherein said solvent comprises a propylene dicaprylate or dicaprate or a mixture thereof.
Claim 10
Dependent Claim
12 words
A composition according to claim 6 wherein said water-dispersible material is gelatin.
Claim 11
Dependent Claim
62 words
A composition according to claim 2 wherein said compound is selected from those represented by the formula: ##STR3## wherein: R is hydrogen, a lower alkyl group of 1 to 4 carbon atoms, or the pharmaceutically acceptable, non-toxic salts of compounds in which R is hydrogen; and X is hydrogen, o-, m- or p-halo, o, m- or p-methyl or o-, m- or p-methoxy.
Claim 12
Dependent Claim
20 words
A composition according to claim 10 wherein said compound is present in an amount between 0.01 mg to 20 mg/ml.
Claim 13
Dependent Claim
13 words
A composition according to claim 11 wherein said composition is encapsulated in gelatin.
Claim 14
Dependent Claim
26 words
A composition according to claim 12 wherein the compound is (dl)-9-keto-11α,15α-dihydroxy-16-phenoxy-17,18,19,20-tetranorprosta-4,5,13-transtrienoic acid methyl ester and is present in an amount between 0.01 mg to 5 mg/ml.
Claim 15
Independent Claim
48 words
A method for preparing a stable soft-shell gelatin composition of PGE or PGE-type compounds which comprises dissolving at least one of said compounds in a solvent comprising at least one propylene glycol diester of a short chain fatty acid and adding the mixture to a soft-shelled gelatin capsule.
Claim 16
Independent Claim
48 words
A method for preparing a stable soft-shell gelatin composition of PGE or PGE-type compounds which comprises dissolving at least one of said compounds in a solvent comprising at least one propylene glycol diester of a short chain fatty acid and adding the mixture to a soft-shelled gelatin capsule.
Claim 17
Dependent Claim
21 words
The method of claim 14 wherein said compound is present in an amount between 0.001 mg to 100 mg/ml of solvent.
Claim 18
Dependent Claim
15 words
The method of claim 15 wherein said solvent comprises a propylene glycol dicaprylate or dicaprate.
Claim 19
Dependent Claim
61 words
The method of claim 15 wherein said compound is selected from those represented by the formula: ##STR4## wherein: R is hydrogen, a lower alkyl group of 1 to 4 carbon atoms, or the pharmaceutically acceptable, non-toxic salts of compounds in which R is hydrogen; and X is hydrogen, o-, m- or p-halo, o, m- or p-methyl or o-, m- or p-methoxy.
Claim 20
Dependent Claim
19 words
The method of claim 17 wherein said compound is present in an amount between 0.01 mg to 20 mg/ml.
Claim 21
Dependent Claim
18 words
The method of claim 18 wherein said solvent comprises a propylene glycol dicarylate or dicaprate or mixtures thereof.
Claim 22
Dependent Claim
25 words
The method of claim 19 wherein said compound is (dl)-9-keto-11α,15α-dihydroxy-16-phenoxy-17,18,19,20-tetranorprosta-4,5,13-trans-trienoic acid methyl ester and is present in an amount between 0.01 mg to 5 mg/ml.
Claim 23
Independent Claim
31 words
A method for preparing a stable PGE or PGe-type pharmaceutical composition which method comprises dissolving a PGE or PGE-type compound in a propylene glycol dicaprylate or dicaprate solvent or mixtures thereof.
Claim 24
Independent Claim
31 words
A method for preparing a stable PGE or PGe-type pharmaceutical composition which method comprises dissolving a PGE or PGE-type compound in a propylene glycol dicaprylate or dicaprate solvent or mixtures thereof.
Claim 25
Dependent Claim
22 words
The method according to claim 21 wherein said compound is present in an amount between 0.001 mg to 100 mg/ml of solvent.
Claim 26
Dependent Claim
19 words
The method according to claim 22 wherein said solvent comprises a propylene glycol dicaprylate or dicaprate or mixtures thereof.
Claim 27
Dependent Claim
20 words
The method according to claim 22 wherein said solution is contained in a capsule of a pharmaceutically acceptable water-dispersible material.
Claim 28
Dependent Claim
12 words
The method according to claim 24 wherein said water-dispersible material is gelatin.
Claim 29
Dependent Claim
22 words
The method according to claim 25 wherein said compound is present in an amount between 0.01 mg to 20 mg/ml of solvent.
Claim 30
Dependent Claim
17 words
The method according to claim 26 wherein said solution is contained in a pharmaceutically acceptable water-dispersible material.
Claim 31
Dependent Claim
12 words
The method according to claim 27 wherein said water-dispersible material is gelatin.
Claim 32
Dependent Claim
62 words
The method according to claim 22 wherein said compound is selected from those represented by the formula: ##STR5## wherein: R is hydrogen, a lower alkyl group of 1 to 4 carbon atoms, or the pharmaceutically acceptable, non-toxic salts of compounds in which R is hydrogen; and X is hydrogen, o-, m- or p-halo, o, m- or p-methyl or o-, m- or p-methoxy.
Claim 33
Dependent Claim
19 words
The method according to claim 29 said compound is present in an amount between 0.01 mg to 20 mg/ml.
Claim 34
Dependent Claim
13 words
The method according to claim 30 wherein said composition is encapsulated in gelatin.
Claim 35
Dependent Claim
18 words
The method according to claim 31 wherein said solvent comprises propylene glycol dicaprylate or dicaprate or mixtures thereof.
Claim 36
Dependent Claim
26 words
The method according to claim 32 wherein said compound is (dl)-9-keto-11α,15α-dihydroxy-16-phenoxy-17,18,19,20-tetranorprosta-4,5,13-trans-trienoic acid methyl ester and is present in an amount between 0.01 mg to 5 mg/ml.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-10-10 | 1987-04-11 | 1987-10-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-10-10 | 1991-04-11 | 1991-10-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-10-10 | 1995-04-11 | 1995-10-11 | $7700.00 | Window Closed / Lapsed |